<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu D</submitter><funding>National Natural Science Foundation of China</funding><pagination>330</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12751668</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>44(1)</volume><pubmed_abstract>Hepatocellular carcinoma (HCC), often arising from liver fibrosis in nonalcoholic fatty liver disease (NAFLD), remains a leading cause of cancer-related death. Targeting the gut-liver axis offers new therapeutic opportunities to prevent this progression. In this study, colon-targeted chitosan/pectin-based nanoparticles loaded with Astragalus polysaccharide (APs-CS/PT-NPs) were developed to modulate gut microbiota and inhibit liver tumorigenesis. The nanoparticles exhibited robust physicochemical stability and pH-responsive release. In vivo, oral administration of APs-CS/PT-NPs attenuated hepatic steatosis, reduced inflammatory cytokines, and suppressed NAFLD-induced HCC development. 16 S rRNA sequencing revealed restoration of microbial diversity and enhanced production of short-chain fatt</pubmed_abstract><journal>Journal of experimental &amp; clinical cancer research : CR</journal><pubmed_title>Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition.</pubmed_title><pmcid>PMC12751668</pmcid><funding_grant_id>No. 81704054</funding_grant_id><pubmed_authors>Liang Y</pubmed_authors><pubmed_authors>Li R</pubmed_authors><pubmed_authors>Liu D</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Li M</pubmed_authors><pubmed_authors>Ge P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition.</name><description>Hepatocellular carcinoma (HCC), often arising from liver fibrosis in nonalcoholic fatty liver disease (NAFLD), remains a leading cause of cancer-related death. Targeting the gut-liver axis offers new therapeutic opportunities to prevent this progression. In this study, colon-targeted chitosan/pectin-based nanoparticles loaded with Astragalus polysaccharide (APs-CS/PT-NPs) were developed to modulate gut microbiota and inhibit liver tumorigenesis. The nanoparticles exhibited robust physicochemical stability and pH-responsive release. In vivo, oral administration of APs-CS/PT-NPs attenuated hepatic steatosis, reduced inflammatory cytokines, and suppressed NAFLD-induced HCC development. 16 S rRNA sequencing revealed restoration of microbial diversity and enhanced production of short-chain fatt</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-07-15T13:25:14.497Z</modification><creation>2026-07-05T03:08:30.359Z</creation></dates><accession>S-EPMC12751668</accession><cross_references><pubmed>41422246</pubmed><doi>10.1186/s13046-025-03608-z</doi></cross_references></HashMap>